🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

aTyr Pharma, Inc. ATYR R2KPHARMA

Healthcare · Biotechnology · United States
https://atyrpharma.com
Company Profile ↓
$0.50
-90.35% 1Y
Mkt Cap$49.03M
P/E-0.68
P/B0.87
52W High$6.03
52W Low$0.40
Book Value$0.59
EPS (TTM)$-0.74

Company Overview

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.20.

Recent Developments

  • Dec 2025 Revenue of $190.00K (-19.1% YoY); net profit $-74.12M.
  • Trailing 12 Months Year-on-year growth — revenue -19.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR -12.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-12.45%
1 Year:-19.15%

Stock Price Performance

1 Year:-90.35%
6 Months:-39.68%
3 Months:+5.74%
1 Month:-1.00%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 2% of range
$0.40 $6.03
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)45.23 · Neutral
Price Performance
1M-1.00%
3M+5.74%
6M-39.68%
1Y-90.35%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -12.4% CAGR over 5 years.
  • Trading 91.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.68
Industry PE
25.17
Forward P/E
-0.80
PEG Ratio
-
Book Value
$0.59
Price to Book
0.87
P/S
263.91
EV/EBITDA
0.08
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-12.45%
Profit 5Y
-
Revenue (YoY)
-19.15%
Earnings (YoY)
-

Profitability & Returns

ROCE
-99.71%
ROE
-105.63%
ROA
-51.79%
Profit Margin
0.00%
Op Margin
-
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.11
EPS (TTM)
$-0.74

Balance Sheet & Liquidity

Debt/Equity
0.20
Quick Ratio
5.73
Current Ratio
5.78
Debt
$11.70M
Total Assets
$69.83M
Current Assets
$67.58M
Working Capital
$65.09M

Ownership

Promoter Holding
2.45%
Chg in Prom Hold
-0.00%
FII / Inst Holding
39.84%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$49.03M
Total Revenue (TTM)
$190.00K
EBITDA
$-72.63M
Free Cash Flow
$-32.65M
Operating Cash Flow
$-59.08M
Shares Outstanding
98.05M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ATYR aTyr Pharma, Inc. R2KPHARMA 0.50 -0.68 $49.03M 0.00% -99.71% -105.63% -12.45% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----------------94.00K184.00K-8.06M189.00K148.00K-----000353.00K235.00K0000190.00K00-
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses ----------------------------------15.77M20.31M26.93M14.80M11.44M-
Operating Income -10.90M-11.31M--16.11M-15.43M-13.87M--13.21M-11.91M-10.83M--10.22M-9.96M-6.68M--5.88M-5.64M-5.50M-1.86M-6.32M-6.51M-7.20M-10.45M-7.73M-12.38M-12.58M-13.49M-12.79M-13.56M-12.62M-16.64M-17.32M-18.14M-15.77M-20.31M-26.75M-14.80M-11.44M-10.88M
EBITDA -----------------------------------15.39M-19.93M-26.36M-14.40M-11.04M-
Interest Expense ----------------------------------------
Pretax Income -----------------------------------14.88M-19.53M-25.75M-13.96M-10.79M-
Tax Provision ----------------------------------------
Net Income -11.08M-11.33M-16.49M-16.09M-15.38M-13.82M-12.57M-13.40M-12.14M-11.19M-11.47M-10.67M-10.41M-7.11M-6.32M-6.14M-5.85M-5.64M-5.97M1.75M-6.45M-6.60M-7.15M-10.39M-7.67M-12.15M-12.42M-13.24M-11.95M-12.34M-11.34M-15.49M-16.31M-17.26M-14.88M-19.53M-25.74M-13.96M-10.79M-10.31M
Diluted EPS ----------------2.54---0.25---0.51-0.64-0.42-0.44-0.44-0.46-0.29-0.22-0.20-0.23-0.23-0.23-0.17-0.22-0.26-0.14-0.11-0.11
R&D Expense 7.50M7.74M-12.00M11.31M10.39M-9.20M8.42M7.13M-6.15M6.48M4.20M-3.35M3.31M3.80M-3.62M4.36M4.62M4.52M7.66M5.14M8.90M9.13M9.87M9.38M9.84M10.32M13.36M13.97M14.81M11.81M15.38M22.13M-7.32M6.75M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ------422.00K10.46M010.39M353.00K235.00K190.00K
Cost of Revenue -------------
Gross Profit -------------
Operating Expenses ---------56.79M55.27M68.15M77.82M
Operating Income -19.54M-23.55M-47.62M-57.94M-47.15M-32.82M-22.98M-15.91M-34.02M-46.40M-54.92M-67.91M-77.63M
EBITDA ----------44.71M-52.18M-66.37M-76.07M
Interest Expense -------------
Pretax Income ----------45.34M-50.40M-64.02M-74.12M
Tax Provision -------------
Net Income -20.01M-24.35M-47.97M-57.85M-48.21M-34.52M-16.22M-16.22M-33.77M-45.34M-50.39M-64.02M-74.12M
Diluted EPS --------1.77-1.77-1.60-0.94-0.86-0.80
R&D Expense 13.83M16.78M34.50M42.85M30.07M20.39M14.05M17.29M23.26M42.81M42.29M54.37M60.22M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --20.64M129.68M80.52M89.36M52.75M36.19M38.73M-95.79M120.65M96.83M93.00M
Current Assets ----------80.87M102.99M81.95M80.24M
Cash & Equivalents 3.67M36.46M13.90M53.02M38.39M21.09M22.96M9.21M16.95M-9.98M22.54M11.05M10.74M
Inventory --------------
Receivables ----------11.78M2.44M1.74M873.00K
Total Liabilities ----------24.50M30.18M27.00M25.71M
Current Liabilities --10.11M12.15M8.53M10.39M10.83M12.92M5.86M-13.86M16.42M14.97M15.15M
Long Term Debt ---1.78M9.20M14.72M8.26M-------
Total Debt ----------11.53M15.10M13.28M12.03M
Total Equity -64.55M-66.08M-91.01M115.05M62.80M64.25M33.65M21.19M31.65M-71.46M90.66M70.02M67.48M
Shares Outstanding ----------29.50M63.29M84.04M98.03M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----52.86M-42.36M-31.06M-20.01M-15.30M--41.89M-33.22M-69.12M-61.99M
Investing Cash Flow ---33.53M-27.64M37.17M4.92M6.90M-47.24M-20.13M17.23M-5.05M
Financing Cash Flow ---4.70M52.70M-4.24M1.34M16.14M-5.45M66.23M39.86M66.01M
Capital Expenditure -644.00K-249.00K-664.00K-600.00K-1.31M-594.00K-79.00K-202.00K--1.64M-4.21M-65.00K-77.00K
Free Cash Flow ----53.46M-43.68M-31.66M-20.09M-15.50M--43.53M-37.44M-69.18M-62.06M
Net Change in Cash ---------10.81M12.88M-12.02M-1.03M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % -------5,445.0%-152.2%--446.8%-15,557.8%-28,899.6%-40,856.3%
Net Margin % -------3,844.5%-155.2%--436.5%-14,274.5%-27,243.8%-39,009.5%
ROE % 30.3%26.8%-41.7%-92.1%-75.0%-102.6%-76.6%-51.3%--63.4%-55.6%-91.4%-109.8%
ROCE % --223.7%-40.5%-80.5%-59.7%-78.3%-98.8%-48.4%--56.6%-52.7%-83.0%-99.7%

Shareholding Pattern

Insiders
2.45%
Institutions
39.84%
Public Float
40.84%

Top Institutional Holders

#Holder% HeldSharesValue
1 Federated Hermes, Inc. 8.68% 8.51M $4.60M
2 Vanguard Capital Management LLC 3.88% 3.81M $2.06M
3 GSA Capital Partners LLP 3.52% 3.45M $1.87M
4 AQR Capital Management, LLC 2.66% 2.61M $1.41M
5 FMR, LLC 2.52% 2.47M $1.33M
6 Blackrock Inc. 1.86% 1.83M $986.76K
7 Kalehua Capital Management LLC 1.82% 1.79M $965.61K
8 Jane Street Group, LLC 1.75% 1.72M $929.50K
9 UBS Group AG 1.56% 1.53M $826.82K
10 Morgan Stanley 1.37% 1.34M $725.56K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ATYR

Google News ue, 01 Sep 2026

FDA response expected by mid-September for aTyr’s lung disease trial - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNYndocnA1c1FhRzE1R0ZkY3ZHTE1fWENtS19UeGtrQ3EtSmFBdkZucjNuMHFJRDkxN3pTckozUHFuNXJ4V3NYSHBubTBQem9OejlfOXlXcTBVX2RyN1dUdVRlRFJ5Y3RQY3B6MFcyYjA3UTlXLV91dVdhcVBCLVJiUzRmbi1mMHN6YU1ORn…

Google News ue, 01 Sep 2026

aTyr Pharma Provides Update on FDA Response Timing for Planned Phase 3 Efzofitimod Sarcoidosis Study - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQc3hCS05RWnpUWTZpOGxLMHh3VV9wdTdZUGdKZXNzQVBqM010VlZPQ1EtNkhBX05QbkFBLTBhamh1Ukk2OGNZOWQtMHFwS0xidTN1eDhFRmZvY0FSQU9DbzRWUExjbV8tS3N2dGxnN3lrajFwbUoxb0s0MWJIZHZwQkcxWVk3UG5xemNTcV…

Google News Fri, 04 Sep 2026

aTyr Pharma (ATYR) Revenue Breakdown - Main Composition - Moomoo

<a href="https://news.google.com/rss/articles/CBMisgJBVV95cUxQUjVFQW1sSTB6eG4zazd5OENxRzByMmxmVlhkd2ktZHdEYWJZRmgtVDhMLVM0OERiZXJEeUlEXzFKa1djRlJNSDNwaTdiTlpHSXFBc1FGOUhSSk9HTFV5Vm9mMjgxUGJreHN2YVkxdUk5WUFDRUZsdzItMmlramUyMTVRbXp5TnRENDdkY1…

Google News Mon, 10 Aug 2026

Why is aTyr Pharma stock gaining today? - Investing.com

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOTUNBeHdmWGJ2UmJQVHVOLWxKOFo3M0dLYlRYZ3AtV2FtUjEwN1VpX3dNc0l4MWkzZmlNNDJDblZ0eDJUVG5NWmJqeklidUM5QjBVZUItN1hGVFdIdGUtMVY3SUZ0YVpQdzY0R0M1ZDFzdFY1Zlk3MThGamhIc0ZGcGV2QjFmTHdDeS1vUU…

Google News Fri, 14 Aug 2026

Here's Why We're A Bit Worried About aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNRUs0eXhTeHQ3UGs2VzJuNXMxU1h3VlpMYXRCZ0c5MmUxTmtnRnBKTmNrUHhjYWdOY1RETWtuZUljV0t4MEdhbUdyYWRNVk40ZVJWTVowT1l5OHVJRDhDTWt3WDlJNlV3YnpCbm9uTnU5WnhuSFNIYTYwZjlJVldvZzVoTEZZb2dpZXNpMU…

Google News hu, 25 Jun 2026

ATYR Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1pX2pVQVJLWXB5elI4UExacUt2dlkzLWcyMWUxU0JNbzZaWVZqWVliQUtEN2gzMGJrdlZMUHF5d1BQcnRHZ2poUUNsVGtQclBDZEhGaU84NGwxbDYtNWpocTRDR29wcDBxc3RmVDVlT2IxZVhva2lzSHRR?oc=5" target="_blank">ATY…

ATYR — Frequently Asked Questions

What is the current share price of aTyr Pharma, Inc. (ATYR)?

As of 2026-09-07 16:24 PDT, aTyr Pharma, Inc. (ATYR) trades at $0.50 on NasdaqCM. Its 52-week range is $0.40 to $6.03.

What is the market capitalisation of ATYR?

aTyr Pharma, Inc. (ATYR) has a market capitalisation of $49.03M on NasdaqCM.

What is the P/E ratio of ATYR?

ATYR trades at a trailing price-to-earnings (P/E) ratio of -0.68. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.87.

What is the return on equity (ROE) of ATYR?

ATYR has a return on equity (ROE) of -105.63%. Its return on capital employed (ROCE) is -99.71%.

Is ATYR a good stock to buy?

This page provides a data-driven analysis of aTyr Pharma, Inc. (ATYR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space